Last $2.07 USD
Change Today -0.04 / -1.90%
Volume 1.7M
STEM On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/9/14 All times are local (Market data is delayed by at least 15 minutes).

stemcells inc (STEM) Key Developments

StemCells, Inc. Appoints Alan Trounson to Board of Directors

StemCells Inc. announced the appointment of Alan Trounson, Ph.D. to its Board of Directors. Dr. Trounson most recently served as President of The California Institute of Regenerative Medicine (CIRM).

StemCells Inc. - Special Call

To discuss the interim results from the Phase I/II clinical trial of HuCNS-SC cells in dry AMD

StemCells, Inc. Interim Results Show Improvement in Visual Function and Slowing of Disease Progression in Phase I/II Dry Amd Trial

StemCells Inc. reported positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SC(R) human neural stem cell platform in dry age-related macular degeneration at the 12th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada. Interim trial results show a 65% reduction in the rate of geographic atrophy (GA) in the study eye when compared to the expected natural history of the disease as well as a 70% reduction in the rate of GA when compared to the control eye. GA is the progressive loss of two important retinal tissue layers, the photoreceptors and the retinal pigmented epithelium. This degeneration is the cause of vision loss in dry AMD. Interim results also indicate improvements in visual function, as measured by the ability to distinguish shades of light versus dark, also referred to as "contrast sensitivity." Contrast sensitivity was improved in four of the seven patients and remained stable in the other three patients. The interim analysis is based on a minimum follow up of at least 6 months and demonstrates a favorable safety profile for administration of the HuCNS-SC cells into the sub-retinal space of the study eye.

StemCells Inc. Presents at BIO International Convention, Jun-25-2014 04:15 PM

StemCells Inc. Presents at BIO International Convention, Jun-25-2014 04:15 PM. Venue: San Diego Convention Center, San Diego, California, United States. Speakers: Martin M. McGlynn, Chief Executive Officer, President, Director, Member of Strategic Transactions Committee, Chief Executive Officer of StemCells California Inc and President of StemCells California Inc.

StemCells Inc. Strengthens Senior Executive Team

StemCells Inc. announced one promotion and three new appointments to the company's executive team. Stephen Huhn, M.D., F.A.C.S., F.A.A.P. has been promoted to the newly created position of vice president, CNS clinical research and chief medical officer. Joel Naor, M.D., M.B.A., M.Sc., has joined StemCells Inc. as vice president, clinical development, ophthalmology, and will report to Dr. Stephen Huhn; Naymisha Patel has joined StemCells Inc. as vice president, quality systems; and Mohammad A. El-Kalay, Ph.D. has joined StemCells Inc. as vice president, process development. Dr. Huhn, Ms. Patel and Dr. El-Kalay will report to Martin McGlynn president and chief executive officer of StemCells Inc. As chief medical officer, Dr. Huhn will continue to oversee all aspects of the company's clinical activities. Dr. Naor brings more than 14 years of experience drug development for retinal conditions, and will be responsible for the development of cell-based products for retinal diseases, initially from the company's proprietary HuCNS-SC(R) platform technology. Naymisha Patel will be responsible for driving the corporate quality agenda and implementing Quality Management Systems appropriate for planned clinical and manufacturing growth. Mohammad A. El-Kalay, Ph.D., will be responsible for developing scalable and efficient manufacturing processes and assays to meet the increasing clinical and development demand for products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STEM:US $2.07 USD -0.04

STEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aastrom Biosciences Inc $3.74 USD -0.035
Athersys Inc $1.73 USD -0.05
Bioheart Inc $0.03 USD -0.0029
BioTime Inc $2.73 USD +0.02
Cytori Therapeutics Inc $2.23 USD -0.01
View Industry Companies
 

Industry Analysis

STEM

Industry Average

Valuation STEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 92.8x
Price/Book 15.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 59.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMCELLS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.